
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding: A Synthesis of AASLD 2020 & EASL 2025 Guidances</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding: A Synthesis of AASLD 2020 & EASL 2025 Guidances</strong></summary>
            <div>
                <ul><li>- <b>Source 1 (AASLD 2020):</b> Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, Jan 2021.</li><li>- <b>Source 2 (EASL 2025):</b> EASL Clinical Practice Guidelines on vascular diseases of the liver. Journal of Hepatology, 2025.</li><li>- This mind map synthesizes and compares recommendations from both major guidelines, highlighting areas of consensus and unique contributions from each.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended AFP cutoff for suspecting HCC in a patient with Budd-Chiari Syndrome (BCS)?</li><li>- In children with Extrahepatic Portal Vein Obstruction (EHPVO), what is the preferred surgical correction?</li><li>- What is the only FDA-approved treatment for severe Sinusoidal Obstruction Syndrome (SOS)?</li><li>- What is the typical mortality rate from a ruptured Hepatic Artery Aneurysm (HAA)?</li><li>- In patients with recent PVT without cirrhosis, what percentage achieve complete recanalization with anticoagulation therapy according to a large prospective trial?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hemostasis & Coagulation in Cirrhosis (AASLD Focus)</strong></summary>
            <div>
                <ul><li>- Cirrhosis is no longer seen as a simple bleeding tendency, but a complex disturbance of both pro- and anti-hemostatic pathways.</li><li>- This leads to a 'rebalanced' but unstable hemostatic system.</li></ul>
                
        <details>
            <summary><strong>Key Hemostatic Changes</strong></summary>
            <div>
                <ul><li>- <b>Promoting Bleeding:</b></li><li>- <u>Thrombocytopenia</u> & platelet function defects.</li><li>- Low levels of coagulation factors (II, V, VII, IX, X, XI).</li><li>- Hyperfibrinolysis (elevated tPA).</li><li>- <b>Promoting Clotting:</b></li><li>- Elevated levels of <u>von Willebrand factor (VWF)</u> & Factor VIII.</li><li>- Decreased levels of natural anticoagulants (Protein C, S, Antithrombin).</li><li>- Decreased levels of plasminogen.</li></ul>
                
        <details>
            <summary><strong>Net Effect</strong></summary>
            <div>
                <ul><li>- The net effect is a fragile balance.</li><li>- Patients can have both bleeding and thrombotic risks simultaneously.</li><li>- Decompensation often favors hyperfibrinolysis, while ACLF/sepsis can severely inhibit it.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Laboratory Assessment</strong></summary>
            <div>
                <ul><li>- Traditional tests like <b>PT/INR</b> and <b>aPTT</b> are <u>inadequate and often misleading</u> for assessing bleeding risk in cirrhosis.</li><li>- They only measure procoagulant factors and ignore the counterbalancing reduction in anticoagulant proteins.</li></ul>
                
        <details>
            <summary><strong>Limitations of PT/INR</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> PT/INR has <u>no predictive value</u> for procedural or spontaneous bleeding in cirrhosis.</li><li>- It is a marker of liver disease severity (synthetic function), not hemostatic competency.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Global Hemostasis Tests</strong></summary>
            <div>
                <ul><li>- Tests like Thromboelastography (<b>TEG</b>) / Rotational Thromboelastometry (<b>ROTEM</b>) and thrombin generation assays provide a better overall picture.</li><li>- They often show that patients with cirrhosis have normal to elevated thrombin-generating capacity and near-normal clot formation.</li></ul>
                
        <details>
            <summary><strong>Clinical Utility & Limitations</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> The predictive value of these tests for procedural bleeding is <u>unproven and contradictory</u>.</li><li>- They may be useful in selecting patients who do <u>not</u> need preprocedural intervention (if results are normal).</li><li>- They are insensitive to VWF and Protein C, likely underestimating hemostatic competency.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Procedural Bleeding in Cirrhosis (AASLD Focus)</strong></summary>
            <div>
                <ul><li>- Bleeding during procedures can be due to hemostatic failure, portal hypertension, or direct vessel injury.</li><li>- Interventions should target the specific cause.</li></ul>
                
        <details>
            <summary><strong>Bleeding Risk Stratification</strong></summary>
            <div>
                <ul><li>- Risk assessment is complex and depends on procedural, liver disease, and systemic factors.</li></ul>
                
        <details>
            <summary><strong>Procedure Risk Categories (AASLD)</strong></summary>
            <div>
                <ul><li>- <b>Low Risk:</b> Major bleeding expected in <q><u><1.5%</u></q> of cases. Bleeding is easily controlled.</li><li>- Examples: Paracentesis, thoracentesis, diagnostic EGD, routine variceal banding.</li><li>- <b>High Risk:</b> Major bleeding risk <q><u>>1.5%</u></q> or bleeding is difficult to control or catastrophic.</li><li>- Examples: Liver biopsy, TIPS, polypectomy, dental extraction.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Disease Factors</strong></summary>
            <div>
                <ul><li>- Advanced portal hypertension is an independent risk factor for bleeding.</li><li>- <b>ACLF</b> and systemic inflammation directly alter hemostasis and increase bleeding risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Systemic Factors</strong></summary>
            <div>
                <ul><li>- <b>Acute and Chronic Kidney Disease (CKD)</b> are significant risk factors for bleeding.</li><li>- In one study of large-volume paracentesis, <q><u>89% (8 of 9)</u></q> of patients with bleeding events had renal dysfunction.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Preprocedural Interventions</strong></summary>
            <div>
                <ul><li>- <b>AASLD strongly advises against</b> the routine prophylactic correction of laboratory abnormalities before common procedures.</li></ul>
                
        <details>
            <summary><strong>Platelet Interventions</strong></summary>
            <div>
                <ul><li>- There is <u>no data-driven specific platelet cutoff</u> where bleeding risk is reliably increased.</li><li>- Prophylactic platelet transfusions do not substantially improve thrombin generation and carry risks (e.g., TRALI).</li><li>- <b>AASLD Recommendation:</b> It is reasonable to perform both low- and high-risk procedures <u>without</u> prophylactically correcting the platelet count.</li></ul>
                
        <details>
            <summary><strong>Thrombopoietin (TPO) Receptor Agonists</strong></summary>
            <div>
                <ul><li>- <b>Avatrombopag</b> and <b>lusutrombopag</b> are FDA-approved to increase platelet counts before a procedure.</li><li>- They are superior to placebo in achieving a target platelet count of <q><u>≥50,000/μL</u></q>.</li><li>- However, studies showed <u>no statistical difference in postprocedural bleeding events</u> compared to placebo.</li><li>- An earlier agent, <b>eltrombopag</b>, was associated with excess thrombotic events (especially PVT).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Coagulation Interventions (INR Correction)</strong></summary>
            <div>
                <ul><li>- The INR <u>should not be used</u> to gauge procedural bleeding risk.</li><li>- Prophylactic <b>Fresh Frozen Plasma (FFP)</b> transfusion is associated with risks (volume overload, increased portal pressure, TRALI) and <u>no proven benefits</u>.</li><li>- FFP shows minimal efficacy in improving thrombin generation in vitro.</li><li>- <b>AASLD Recommendation:</b> Measures aimed at reducing the INR (e.g., FFP) are <u>not recommended</u> before procedures.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fibrinogen Correction</strong></summary>
            <div>
                <ul><li>- Plasma fibrinogen levels <q><u><100 mg/dL</u></q> are associated with bleeding in critically ill patients, but a causal link is not established.</li><li>- <b>AASLD Suggestion:</b> Correction of plasma fibrinogen to levels <q><u>>100 mg/dL</u></q> using cryoprecipitate or fibrinogen concentrate <u>could be considered</u> before high-risk procedures, but supporting data is lacking.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Antifibrinolytic Therapy</strong></summary>
            <div>
                <ul><li>- Agents like Epsilon-aminocaproic acid (EACA) and tranexamic acid are used for hyperfibrinolytic bleeding.</li><li>- A large trial of tranexamic acid in acute GI bleeding showed <u>no reduction in death or bleeding</u> and a higher risk of VTE in the cirrhosis subgroup.</li><li>- <b>AASLD Recommendation:</b> Prophylactic use of these agents to prevent procedural bleeding <u>cannot be recommended</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Portal Vein Thrombosis (PVT)</strong></summary>
            <div>
                <ul><li>- Formation of a thrombus in the portal vein or its branches. Can occur with or without cirrhosis.</li></ul>
                
        <details>
            <summary><strong>Terminology & Classification</strong></summary>
            <div>
                <ul><li>- Both guidelines emphasize the need for standardized terminology to allow for comparison across studies.</li></ul>
                
        <details>
            <summary><strong>AASLD/EASL Recommended Nomenclature</strong></summary>
            <div>
                <ul><li>- <b>Time Course:</b></li><li>- <u>Recent:</u> Presumed to be <q><b><6 months</b></q> old.</li><li>- <u>Chronic:</u> Persistent for <q><b>>6 months</b></q>.</li><li>- <b>Occlusion:</b></li><li>- <u>Minimally:</u> <q><50%</q> of lumen obstructed.</li><li>- <u>Partially:</u> <q>>50%</q> of lumen obstructed.</li><li>- <u>Completely:</u> No persistent lumen.</li><li>- <b>Cavernous Transformation:</b> Presence of gross portoportal collaterals. This term is preferred over 'chronic PVT' when present.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Classification Systems</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Reviews multiple systems (Yerdel, Sarin, etc.), noting most were developed for liver transplant (LT) candidates and lack long-term outcome correlation in non-transplant patients.</li><li>- <b>EASL:</b> Also highlights the Yerdel classification's utility for LT surgical strategy but notes its limitations. Endorses the standardized nomenclature for broader use.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PVT in Patients with Cirrhosis</strong></summary>
            <div>
                <ul><li>- PVT is a common complication in advanced liver disease.</li></ul>
                
        <details>
            <summary><strong>Prevalence & Risk Factors</strong></summary>
            <div>
                <ul><li>- <b>Prevalence:</b> Reported between <q>1.3% and 9.8%</q> in patients with cirrhosis, reaching up to <q>9%</q> in LT candidates.</li><li>- <b>Prospective Incidence:</b> <q>3.2% to 4.1%</q> at 1 year after cirrhosis diagnosis.</li></ul>
                
        <details>
            <summary><strong>Key Risk Factors</strong></summary>
            <div>
                <ul><li>- <b>Severity of Liver Disease:</b> The most significant factor. PVT is a marker of advanced portal hypertension.</li><li>- <b>Decreased PV Flow Velocity:</b> A threshold of <q><u><15 cm/s</u></q> is often cited as a risk factor.</li><li>- <b>Etiology of Cirrhosis:</b></li><li>- <b>AASLD & EASL:</b> Both identify <b>NASH/MASLD</b> as an independent risk factor.</li><li>- <b>EASL:</b> Notes autoimmune liver diseases are also associated.</li><li>- <b>Thrombophilia Workup:</b></li><li>- <b>AASLD & EASL Consensus:</b> An extensive thrombophilia workup is <u>not generally recommended</u> in patients with cirrhosis, as it rarely changes management.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Ruling out Malignancy</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> It is <u>mandatory</u> to rule out malignant venous obstruction due to <b>HCC</b> with contrast-enhanced imaging.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Impact on Mortality & Outcomes</strong></summary>
            <div>
                <ul><li>- The role of PVT as a cause vs. a consequence of disease progression is debated.</li></ul>
                
        <details>
            <summary><strong>Non-Transplant Setting</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Literature is contradictory. Some studies suggest PVT is a consequence of decompensation and not an independent mortality risk. Others (e.g., enoxaparin prevention trial) imply a causal role by showing a survival benefit with PVT prevention.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Transplant (LT) Setting</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> The presence of PVT at the time of transplant, especially occlusive PVT, is associated with <u>increased technical difficulty and post-transplant mortality</u>.</li><li>- <b>AASLD:</b> Notes that there are no RCTs to prove that pre-transplant treatment of PVT improves post-transplant outcomes.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment: Anticoagulation</strong></summary>
            <div>
                <ul><li>- The primary goals are to prevent thrombus extension, maintain portal vein patency for potential LT, and manage portal hypertension complications.</li></ul>
                
        <details>
            <summary><strong>Indications for Treatment</strong></summary>
            <div>
                <ul><li>- <b>EASL & AASLD Consensus for LT Candidates:</b> Anticoagulation <u>should be used</u> to improve feasibility and outcomes of LT, regardless of PVT degree.</li><li>- <b>EASL & AASLD for Non-LT Candidates:</b></li><li>- <u>Occlusive or >50% occlusive PVT:</u> Anticoagulation <u>should be considered/may be used</u>.</li><li>- <u>Minimally occlusive (<50%) PVT:</u> Observation with serial imaging is reasonable. Treat if it progresses.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Spontaneous recanalization occurs in up to <q>40%</q> of cases.</li><li>- <b>AASLD Meta-analysis:</b> Complete PVR occurred in <q><b>42%</b></q> of patients with anticoagulation vs. <q><b>13%</b></q> without.</li><li>- <b>EASL Meta-analysis:</b> Anticoagulation reduced all-cause mortality (HR <q>0.6</q>).</li><li>- Both guidelines note that therapy is most effective if started within <q><u>6 months</u></q> of diagnosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Choice of Anticoagulant</strong></summary>
            <div>
                <ul><li>- <b>Traditional Agents (LMWH/VKAs):</b> Historically the standard. Monitoring INR for VKAs is challenging in cirrhosis.</li><li>- <b>Direct Oral Anticoagulants (DOACs):</b></li><li>- <b>AASLD (2020):</b> Data is sparse and limited to well-compensated cirrhosis. Cautions use due to lack of large trials.</li><li>- <b>EASL (2025):</b> More current view. Recommends DOACs <u>can be used</u> in patients with <b>Child-Pugh A or B</b> cirrhosis. They are <u>not recommended</u> in <b>Child-Pugh C</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Safety & Bleeding Risk</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Therapeutic anticoagulation appears to have similar non-portal hypertensive bleeding rates compared to the general population.</li><li>- Portal hypertension-related bleeding (e.g., variceal) does not appear to be increased by anticoagulants.</li><li>- Both guidelines state that EVL can likely be performed safely without stopping anticoagulation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment: TIPS</strong></summary>
            <div>
                <ul><li>- TIPS can be used for PVT, especially with portal hypertension complications.</li></ul>
                
        <details>
            <summary><strong>Indications</strong></summary>
            <div>
                <ul><li>- <b>EASL & AASLD Consensus:</b> TIPS should be considered for patients with PVT and complications of portal hypertension (e.g., variceal bleeding, refractory ascites).</li><li>- <b>EASL:</b> Also suggests TIPS for PVT that progresses despite anticoagulation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anticoagulation Post-TIPS</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Cites an RCT showing no clear benefit of anticoagulation after covered TIPS for PVT. Recommends that routine anticoagulation is <u>not needed</u> to improve recanalization rates after TIPS.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PVT in Patients without Cirrhosis</strong></summary>
            <div>
                <ul><li>- A rare disease where a thorough workup for underlying causes is crucial.</li></ul>
                
        <details>
            <summary><strong>Risk Factors & Workup</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> A full investigation for <b>myeloproliferative neoplasms (MPN)</b> and other thrombophilic conditions is <u>warranted</u>, often with a hematologist.</li><li>- <b>EASL:</b> Notes abdominal cancer is present in up to <q>30%</q> of cases, and inflammatory/infectious abdominal diseases in <q>20-30%</q>.</li><li>- <b>AASLD:</b> Highlights that the G20210A prothrombin gene mutation is most prevalent among inherited thrombophilias in this setting.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Goals of Therapy & Treatment</strong></summary>
            <div>
                <ul><li>- Aims are to prevent thrombus extension, avoid intestinal ischemia, and achieve recanalization to prevent portal hypertension.</li></ul>
                
        <details>
            <summary><strong>Anticoagulation</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Anticoagulation should be initiated <u>as soon as possible</u>.</li><li>- <b>Efficacy:</b> A large prospective trial (AASLD) showed anticoagulation achieved complete recanalization in <q><b>38%</b></q> of the cohort.</li><li>- <b>Duration (EASL):</b> For patients with a major and permanent risk factor, long-term anticoagulation is recommended. For others, it can be considered based on risk of recurrence.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>DOACs vs. Traditional Agents</strong></summary>
            <div>
                <ul><li>- <b>AASLD (2020):</b> Notes DOAC use is becoming commonplace despite exclusion from large trials. Cites a retrospective study showing superior efficacy and less bleeding for DOACs vs. warfarin.</li><li>- <b>EASL (2025):</b> Suggests DOACs as an alternative to LMWH/VKAs in the acute phase and that they may be preferred over VKAs for long-term therapy to improve adherence and safety.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Interventional Therapies</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Local/systemic thrombolysis should only be considered in selected cases where intestinal ischemia persists despite anticoagulation.</li><li>- <b>EASL:</b> Agrees that thrombolysis should be reserved for severe disease after medical treatment fails.</li><li>- Both guidelines suggest portal vein recanalization (PVR) +/- TIPS for refractory complications of portal hypertension.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatic Vein Thrombosis (Budd-Chiari Syndrome)</strong></summary>
            <div>
                <ul><li>- Obstruction of hepatic venous outflow from small hepatic veins to the junction of the IVC and right atrium.</li></ul>
                
        <details>
            <summary><strong>Etiology & Diagnosis</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> An underlying prothrombotic disorder is found in <q>~75%</q> of patients. A full thrombophilia workup is recommended.</li><li>- <b>Most Common Cause (Western):</b> Myeloproliferative neoplasia (MPN), found in <q>~41%</q> of cases.</li><li>- <b>Diagnosis:</b> Doppler ultrasound is the first-line imaging study. CT/MRI confirms the diagnosis and aids in planning.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Strategy</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> A progressive, <u>stepwise therapeutic strategy</u> is recommended, managed at expert centers.</li></ul>
                
        <details>
            <summary><strong>Step 1: Medical Therapy</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL:</b> All patients should receive therapeutic anticoagulation, initiated immediately.</li><li>- <b>EASL:</b> Recommends <b>LMWH</b> followed by <b>VKAs</b>. Unfractionated heparin should be avoided due to high risk of heparin-induced thrombocytopenia. DOACs may be considered with preserved liver function.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Step 2: Interventional Procedures</strong></summary>
            <div>
                <ul><li>- <b>Angioplasty +/- Stenting:</b> For patients with short, segmental stenosis.</li><li>- <b>Thrombolysis:</b> Limited role; only for selected cases of recent, incomplete thrombosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Step 3: Vascular Decompression (TIPS)</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL:</b> TIPS (or DIPS) is the treatment of choice when medical therapy or angioplasty fails.</li><li>- It is technically challenging and should be performed at expert centers.</li><li>- <b>AASLD:</b> 5-year transplant-free survival after TIPS is <q>72%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Step 4: Liver Transplantation (LT)</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL:</b> Reserved for patients who fail less invasive approaches or present with acute liver failure.</li><li>- 5-year survival rates are <q>>70%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HCC Surveillance in Chronic BCS</strong></summary>
            <div>
                <ul><li>- Patients with chronic BCS are at risk for developing HCC.</li></ul>
                
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Surveillance for HCC with ultrasound +/- alpha-fetoprotein every <q><u>6 months</u></q> is recommended.</li><li>- <b>AASLD:</b> An AFP level of <q><u>>15 ng/mL</u></q> has been suggested as a predictive biomarker for HCC in BCS.</li><li>- <b>EASL:</b> Confirms that an AFP >15 ng/ml should raise suspicion.</li><li>- <b>Diagnosis:</b> Both guidelines state that due to altered vascularity, standard imaging criteria (e.g., LI-RADS) do not apply, and <u>histological confirmation</u> is required for suspicious lesions.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Sinusoidal Obstruction Syndrome (SOS)</strong></summary>
            <div>
                <ul><li>- Also known as veno-occlusive disease (VOD), characterized by toxic/inflammatory damage to sinusoidal endothelial cells, leading to occlusion of small hepatic venules.</li></ul>
                
        <details>
            <summary><strong>Etiology & Diagnosis</strong></summary>
            <div>
                <ul><li>- <b>Most Common Setting:</b> Complication of myeloablative chemotherapy before hematopoietic stem cell transplantation (HSCT).</li><li>- <b>Key Drugs:</b> Alkylating agents (busulfan, cyclophosphamide), platinum complexes (oxaliplatin), thiopurines, gemtuzumab.</li><li>- <b>Clinical Presentation:</b> Acute onset (1-3 weeks post-exposure) of right upper quadrant pain, weight gain, hepatomegaly, and ascites.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prophylaxis in HSCT</strong></summary>
            <div>
                <ul><li>- Strategies to prevent SOS in high-risk patients undergoing HSCT.</li></ul>
                
        <details>
            <summary><strong>Ursodeoxycholic Acid</strong></summary>
            <div>
                <ul><li>- <b>AASLD (2020):</b> Notes mixed data from RCTs but a meta-analysis suggests overall benefit.</li><li>- <b>EASL (2025):</b> Cites a Cochrane meta-analysis showing reduction in mortality. <u>Recommends</u> prophylaxis with ursodeoxycholic acid in all patients.</li><li>- <b>Dose:</b> <q><b>12-15 mg/kg/day</b></q> starting before conditioning and continuing for 3 months.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Defibrotide</strong></summary>
            <div>
                <ul><li>- <b>AASLD (2020):</b> States benefit of prophylactic use is unproven and costs are high.</li><li>- <b>EASL (2025):</b> Cites the recent large HARMONY trial which showed <u>no benefit</u> for defibrotide prophylaxis. <u>Generally does not recommend</u> its use for prevention.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Management of established SOS.</li></ul>
                
        <details>
            <summary><strong>Defibrotide</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Defibrotide is the <u>only FDA/EU-approved treatment</u> for SOS.</li><li>- <b>Indication:</b> Recommended for moderate-to-severe (AASLD) or severe (EASL) SOS.</li><li>- <b>EASL:</b> Suggests it can be considered for moderate SOS and that early initiation is preferable.</li><li>- <b>Dose:</b> <q><b>25 mg/kg/day</b></q> for at least 21 days.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>TIPS</strong></summary>
            <div>
                <ul><li>- <b>AASLD (2020):</b> States TIPS is unproven and cannot be recommended.</li><li>- <b>EASL (2025):</b> Cites recent positive experiences and suggests TIPS <u>may be considered</u> in severe/very severe SOS with rapid deterioration despite medical therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>SOS outside HSCT (e.g., Oxaliplatin)</strong></summary>
            <div>
                <ul><li>- <b>EASL:</b> Oxaliplatin is a major cause of SOS, often presenting with imaging changes (mosaic pattern) and splenomegaly without significant enzyme elevation.</li><li>- In the long term, it can lead to PSVD with portal hypertension.</li><li>- <b>Treatment:</b> Both guidelines suggest stopping the offending drug if possible. EASL notes that bevacizumab may protect against oxaliplatin-induced SOS.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Portosinusoidal Vascular Disorder (PSVD) / INCPH</strong></summary>
            <div>
                <ul><li>- A group of entities characterized by portal hypertension in the absence of cirrhosis, PV obstruction, or BCS. EASL prefers the term PSVD, which encompasses AASLD's Idiopathic Noncirrhotic Portal Hypertension (INCPH).</li></ul>
                
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- <b>Suspicion Raised By:</b> Signs of portal hypertension (e.g., variceal bleeding) with discordant findings like mild/no liver dysfunction, low liver stiffness (<q><10 kPa</q>), or low HVPG (<q><10 mmHg</q>).</li><li>- <b>AASLD & EASL Consensus:</b> A <u>liver biopsy</u> is required to exclude cirrhosis and identify characteristic histological lesions (e.g., obliterative portal venopathy, nodular regenerative hyperplasia).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Associated Conditions & Workup</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> An extensive workup for associated conditions is recommended as they have prognostic significance.</li></ul>
                
        <details>
            <summary><strong>Key Associated Conditions</strong></summary>
            <div>
                <ul><li>- <b>Immune Disorders:</b> Common variable immunodeficiency, SLE, IBD. Found in up to <q>32%</q> of patients (EASL).</li><li>- <b>Prothrombotic Conditions:</b> Antiphospholipid syndrome, Protein C/S deficiency.</li><li>- <b>Hematological Disorders:</b> Myeloproliferative disorders, aplastic anemia.</li><li>- <b>Drug Exposure:</b> <u>Didanosine</u>, <u>azathioprine</u>, <u>oxaliplatin</u>, <u>thioguanine</u>.</li><li>- <b>Infections:</b> HIV.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Natural History & Complications</strong></summary>
            <div>
                <ul><li>- <b>Primary Complication:</b> Gastrointestinal bleeding from portal hypertension.</li><li>- Ascites and encephalopathy are less frequent and often triggered by bleeding.</li></ul>
                
        <details>
            <summary><strong>Portal Vein Thrombosis (PVT)</strong></summary>
            <div>
                <ul><li>- PVT is a very common complication.</li><li>- <b>AASLD:</b> Cumulative incidence in INCPH is higher (<q>32%</q>) than in cirrhosis (<q>18%</q>).</li><li>- <b>EASL:</b> Recommends surveillance for PVT every <q>6 months</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatocellular Carcinoma (HCC)</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> HCC is <u>extremely rare</u> in this population.</li><li>- Routine surveillance for HCC is <u>not recommended</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> No established independent therapy for INCPH itself. Management focuses on the complications of portal hypertension, generally following cirrhosis guidelines.</li><li>- <b>EASL:</b> Recommends TIPS or LT for severe or refractory portal hypertension-related complications.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hereditary Hemorrhagic Telangiectasia (HHT) (AASLD Focus)</strong></summary>
            <div>
                <ul><li>- Autosomal dominant genetic disease causing widespread arteriovenous malformations (AVMs).</li><li>- Liver vascular malformations (LVMs) are present in <q>40%-70%</q> of patients.</li></ul>
                
        <details>
            <summary><strong>Pathophysiology & Clinical Presentation</strong></summary>
            <div>
                <ul><li>- Symptoms result from three main types of intrahepatic shunting:</li><li>- <b>Hepatic Artery ---> Hepatic Vein:</b> Leads to <u>high-output heart failure</u> (most common presentation).</li><li>- <b>Hepatic Artery ---> Portal Vein:</b> Leads to <u>portal hypertension</u> (ascites, varices).</li><li>- <b>Portal Vein ---> Hepatic Vein:</b> Leads to <u>portosystemic encephalopathy</u>.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Pitfalls</strong></summary>
            <div>
                <ul><li>- Can be misdiagnosed as cirrhosis due to nodular liver, varices, and ascites.</li><li>- Liver synthetic function and platelet count are usually normal.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- Suspect in patients with a liver bruit, enlarged hepatic artery, and heterogeneous liver enhancement on imaging.</li><li>- A family or personal history of recurrent nosebleeds is a key clue.</li><li>- <b>Liver biopsy is not recommended</b> due to high bleeding risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>- Should be managed at specialized centers with a multidisciplinary approach.</li></ul>
                
        <details>
            <summary><strong>Standard Therapy</strong></summary>
            <div>
                <ul><li>- <b>Asymptomatic LVMs:</b> No therapy or surveillance needed.</li><li>- <b>Symptomatic LVMs:</b> Treat the specific complication (e.g., diuretics for heart failure, standard management for portal hypertension).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Advanced Therapies (for non-responders)</strong></summary>
            <div>
                <ul><li>- <b>Bevacizumab:</b> A monoclonal antibody against VEGF. Improves heart failure and ischemic cholangiopathy.</li><li>- Dose: <q><b>5 mg/kg</b> intravenously every 2 weeks for six doses</q>.</li><li>- <b>Hepatic Artery Embolization/Ligation:</b> <u>Generally not recommended</u> due to risk of hepatic/biliary necrosis.</li><li>- <b>Liver Transplantation:</b> For severe, refractory cases. Associated with high perioperative complications and potential for LVM recurrence in the graft.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatic & Splenic Artery Aneurysms</strong></summary>
            <div>
                <ul><li>- Uncommon vascular lesions, often found incidentally. It's critical to distinguish true aneurysms from pseudoaneurysms (higher rupture risk).</li></ul>
                
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Multidetector <b>CT angiography</b> is the optimal tool for detection, characterization, and treatment planning.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatic Artery Aneurysms (HAAs)</strong></summary>
            <div>
                <ul><li>- Most are true aneurysms caused by atherosclerosis or trauma.</li><li>- <b>Rupture Risk:</b> Reported as high as <q>25%</q> in some clinical series.</li><li>- <b>Mortality from Rupture:</b> <q><u>>30%</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Splenic Artery Aneurysms (SAAs)</strong></summary>
            <div>
                <ul><li>- Most common SAA. Associated with female gender, multiparity, and portal hypertension.</li><li>- <b>Rupture Risk:</b> Much lower than HAA, around <q>3%</q> overall.</li><li>- Risk is negligible for true aneurysms <q><b><2 cm</b></q> in diameter.</li><li>- <b>Mortality from Rupture:</b> <q>20%-36%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management & Intervention</strong></summary>
            <div>
                <ul><li>- Decisions require a multidisciplinary approach (vascular surgery, interventional radiology).</li></ul>
                
        <details>
            <summary><strong>Treatment Indications</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Urgent intervention for <u>symptomatic</u> or <u>complicated</u> aneurysms.</li><li>- Intervention is recommended for:</li><li>- All <b>pseudoaneurysms</b>, regardless of size.</li><li>- True aneurysms that are large (traditionally <q><u>>2 cm</u></q>) or show significant growth on serial imaging.</li><li>- Special populations: Women planning pregnancy and LT candidates.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Modality</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> If intervention is needed, <b>endovascular repair</b> should be considered first. Open surgery is reserved for cases where endovascular approach is not feasible.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance (Conservative Management)</strong></summary>
            <div>
                <ul><li>- For asymptomatic true aneurysms <q><2 cm</q>.</li><li>- <b>AASLD:</b> Recommends early follow-up imaging (e.g., at 3 and 12 months) to assess for growth.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Issues Specific to Children</strong></summary>
            <div>
                <ul><li>- <b>AASLD & EASL Consensus:</b> Early referral to centers with expertise in pediatric liver disease, hepatobiliary surgery, and LT is recommended for all congenital or acquired vascular liver diseases.</li></ul>
                
        <details>
            <summary><strong>Extrahepatic Portal Vein Obstruction (EHPVO)</strong></summary>
            <div>
                <ul><li>- An acquired lesion, often following neonatal umbilical vein catheterization.</li><li>- Presents with variceal bleeding and hypersplenism, but preserved liver function.</li><li>- <b>AASLD:</b> Recommends evaluation for early intervention even in the presymptomatic stage.</li></ul>
                
        <details>
            <summary><strong>Surgical Correction</strong></summary>
            <div>
                <ul><li>- The preferred surgical procedure is the <b>meso-Rex bypass</b> (surgical extrahilar mesenterico/left portal shunt).</li><li>- This corrects physiological abnormalities like minimal hepatic encephalopathy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatic Hemangiomas</strong></summary>
            <div>
                <ul><li>- Can be congenital or infantile. Many can be safely observed as they involute.</li><li>- <b>AASLD:</b> Glutathione expression occurs in <q>30%-50%</q> of infantile hemangiomas.</li><li>- <b>EASL & AASLD:</b> These tumors respond well to nonselective beta-blockers like <b>propranolol</b>, which is the treatment of choice.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Congenital Portosystemic Shunts (Abernethy)</strong></summary>
            <div>
                <ul><li>- Hallmark clinical feature is <b>hyperammonemia</b>.</li><li>- <b>AASLD:</b> Modern <b>endovascular shunt closure</b> techniques have made LT unnecessary in the vast majority of children.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Common Management Issues (EASL Focus)</strong></summary>
            <div>
                <ul><li>- This section covers management principles applicable across various vascular liver diseases, primarily drawing from the more recent EASL 2025 guidelines.</li></ul>
                
        <details>
            <summary><strong>Gastro-esophageal Varices</strong></summary>
            <div>
                <ul><li>- Portal hypertension is a common final pathway for many of these disorders.</li></ul>
                
        <details>
            <summary><strong>Surveillance</strong></summary>
            <div>
                <ul><li>- Endoscopy is recommended when portal hypertension is suspected.</li><li>- <b>Spleen stiffness measurement</b> is a promising non-invasive tool. A value <q><u><40 kPa</u></q> identifies patients with PSVD or portal cavernoma at very low risk of high-risk varices, potentially sparing endoscopy.</li><li>- <b>Follow-up Interval:</b> If no varices, repeat endoscopy in <q>2 years</q>. If small varices, repeat in <q>1 year</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prophylaxis of Bleeding</strong></summary>
            <div>
                <ul><li>- <b>Primary Prophylaxis:</b> Non-selective beta-blockers (NSBBs) or endoscopic variceal ligation (EVL) are recommended for high-risk varices.</li><li>- <b>Secondary Prophylaxis:</b> Combination of NSBBs and EVL.</li><li>- <b>Refractory Bleeding:</b> TIPS is recommended.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pregnancy</strong></summary>
            <div>
                <ul><li>- Pregnancy should be planned when the liver disease and any prothrombotic condition are well-controlled.</li></ul>
                
        <details>
            <summary><strong>Anticoagulation Management</strong></summary>
            <div>
                <ul><li>- <b>VKAs or DOACs must be switched to LMWH</b> as soon as pregnancy is confirmed, and at least before the <q>4th week</q> of gestation.</li><li>- LMWH is continued throughout the pregnancy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Delivery</strong></summary>
            <div>
                <ul><li>- <b>Vaginal delivery</b> is preferred over caesarean section.</li><li>- <b>Platelet Count Thresholds:</b></li><li>- Vaginal Delivery: <q>>20 x 10^9/L</q></li><li>- Caesarean Section: <q>>50 x 10^9/L</q></li><li>- Epidural Anesthesia: <q>>75 x 10^9/L</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-partum & Breastfeeding</strong></summary>
            <div>
                <ul><li>- <b>Oestrogen-containing contraceptives should not be used</b>.</li><li>- Breastfeeding is possible with beta-blockers and <b>warfarin</b>.</li><li>- Other VKAs and DOACs are contraindicated during breastfeeding.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contraception</strong></summary>
            <div>
                <ul><li>- <b>Oestrogen-containing oral contraceptives</b> are associated with an increased risk of thrombosis and should be avoided.</li><li>- <b>Preferred methods:</b> Intrauterine devices (IUDs), mechanical contraception (condoms), and microprogestatives (progestin-only pills).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
